FDA Grants Accelerated Approval to Inovio's VOCERYQ for Throat Condition
Inovio's VOCERYQ received FDA accelerated approval to reduce surgery frequency in adults with Recurrent Respiratory Papillomatosis.
Inovio Pharmaceuticals announced that its treatment VOCERYQ — a combination of doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd — has received accelerated approval from the U.S. Food and Drug Administration, marking a significant regulatory milestone for the biotechnology company. The approval targets adults suffering from Recurrent Respiratory Papillomatosis, a chronic condition caused by viral growths in the airway that typically requires repeated surgical intervention.
The FDA's accelerated approval pathway is designed for therapies that address serious conditions and fill an unmet medical need, allowing drugs to reach patients sooner based on preliminary evidence of benefit. VOCERYQ's clearance under this framework reflects the limited treatment options historically available to RRP patients, who often face multiple surgeries throughout their lives to manage recurring growths.
Read more Squeez Secures $1M from Qentelli to Expand Loyalty Commerce Platform →
Inovio disclosed that VOCERYQ is expected to be available to order and ship in the near term, signaling the company's intent to move quickly from regulatory approval to commercial distribution. The launch would represent Inovio's transition from a clinical-stage developer to a commercial-stage biopharmaceutical company, a threshold that carries significant implications for its revenue outlook and investor profile.
The approval was highlighted as part of Inovio's third-quarter 2026 financial results and recent business update, suggesting the company views VOCERYQ's regulatory clearance as a central driver of its near-term business narrative. Additional operational and financial details were included in the broader earnings release.
Continue reading at Earnings.
